美股異動 | 賽諾菲安萬特(SNY.US)盤前漲近3% 擬投資14.3歐元用於mRNA疫苗技術發展
格隆匯3月8日丨賽諾菲安萬特(SNY.US)盤前漲2.92%,報50.01美元,總市值1264億美元。賽諾菲週一宣佈,計劃在2022 - 26年期間在法國投資14.3億歐元(合15.6億美元),專注於發展由輝瑞、BioNTech和Moderna開發的COVID-19疫苗的mRNA技術。該公司打算建立一個自主的mRNA涵蓋研發到生產的技術價值鏈,並計劃將9.35億歐元用於mRNA技術的發展。另外4.9億歐元的投資還將用於建立一個新的生物生產部門,用於多種疫苗和包括mRNA在內的生物平台。該網站預計將在2025年第四季度上線。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.